LBF20406AM15: Difference between revisions

Latest revision as of 06:42, 8 November 2010

Upper classes: LB LBF

N- ( (S) - (+) -1-Methylpropyl)arachidonoylamide

Structural Information
	N- (d-1S-Methylpropyl)- (cis-5,cis-8,cis-11,cis-14) -eicosatetraenoylamine
	N- ( (S) - (+) -1-Methylpropyl)arachidonoylamide N- ( (S) - (+) -1-Methylpropyl)- (5Z,8Z,11Z,14Z) -eicosatetraenoylamine

Formula	C24H41NO
Exact Mass	359.318814939
Average Mass	359.58847999999995
SMILES	`C(=CCCCC(=O)N[C@H](CC)C)CC=CCC=CCC=CCCCCC`
Physicochemical Information
	colorless oil Sheskin_T et al.


	[ α ]25 4 = +7.08° (C=1, EtOH) Bergstrom_S



	This compound was synthesized from arachidonoylchloride and (S)-(+)-sec-butylamine. Yield 55%. Sheskin_T et al.

	Binding to the brain cannabinoid receptor (CBl), Ki(nM)= 377.2±55.4 Sheskin_T et al.


Spectral Information
Mass Spectra
UV Spectra
IR Spectra
NMR Spectra	¹H NMR (CDCl3) δ 5.30-5.42 (m, 8H), 5.22 (br s, lH), 3.88-3.98 (m, lH), 2.75-2.90 (m, 6H), 2.00-2.20 (m, 6H), 1.65-1.76 (m, 2H), 1.22-1.50 (m, 8H), 1.12 (d, J=7.5Hz, 3H), 0.82-0.96 (m, 6H). Sheskin_Tet al.
Other Spectra
Chromatograms

Reported Metabolites, References

Biospecies	ID	Compound Name	Reference	Comment
n.a.	LBF20406AM15	See above.	Bergstrom_S 1967
n.a.	LBF20406AM15	See above.	Sheskin_T et al. 1997

@@ Line 1: / Line 1: @@
+{{Lipid/Header}}
 {{Hierarchy|{{PAGENAME}}}}
@@ Line 4: / Line 6: @@
 |LipidBank=XPR7031
 |LipidMaps=LMFA08020017
-|SysName=N- ( (S) - (+) -1-methylpropyl) arachidonoyl amide
+|SysName=N- (d-1S-Methylpropyl)- (cis-5,cis-8,cis-11,cis-14) -eicosatetraenoylamine
-|Melting Point=colorless oil <<0001>>
+|Common Name=&&N- ( (S) - (+) -1-Methylpropyl)arachidonoylamide&&N- ( (S) - (+) -1-Methylpropyl)- (5Z,8Z,11Z,14Z) -eicosatetraenoylamine&&
-|Reflactive=dX<sub>4</sub><sup>25</sup>= +7.08° (C=1, EtOH) <<0001>>
+|Melting Point=colorless oil [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]]
-|NMR Spectra=<SUP><FONT SIZE=-1>1</FONT></SUP>H NMR (CDCl3) <FONT FACE="Symbol">d</FONT>5.30-5.42 (m, 8H), 5.22 (br s, lH), 3.88-3.98 (m, lH), 2.75-2.90 (m, 6H), 2.00-2.20 (m, 6H), 1.65-1.76 (m, 2H), 1.22-1.50 (m, 8H), 1.12 (d, J=7.5Hz, 3H), 0.82-0.96 (m, 6H). <<7001>>
+|Optical=[ alpha ]^{25}_4 = +7.08° (C=1, EtOH) [[Reference:Bergstrom_S:,Science,1967,157,382|{{RelationTable/GetFirstAuthor|Reference:Bergstrom_S:,Science,1967,157,382}}]]
+|NMR Spectra=^1 H NMR (CDCl3)  delta 5.30-5.42 (m, 8H), 5.22 (br s, lH), 3.88-3.98 (m, lH), 2.75-2.90 (m, 6H), 2.00-2.20 (m, 6H), 1.65-1.76 (m, 2H), 1.22-1.50 (m, 8H), 1.12 (d, J=7.5Hz, 3H), 0.82-0.96 (m, 6H). [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]]
+|Source=
+|Chemical Synthesis=This compound was synthesized from arachidonoylchloride and (S)-(+)-sec-butylamine. Yield 55%. [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]]
+|Metabolism=
+|Biological Activity=Binding to the brain cannabinoid receptor (CBl), Ki(nM)= 377.2±55.4 [[Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659|{{RelationTable/GetFirstAuthor|Reference:Sheskin_T:Hanus_L:Slager_J:Vogel_Z:Mechoulam_R:,J. Med. Chem.,1997,40,659}}]]
 }}
+{{Lipid/Footer}}

IDs and Links
LipidBank	XPR7031
LipidMaps	LMFA08020017
CAS
KEGG	{{{KEGG}}}
KNApSAcK	{{{KNApSAcK}}}

mol	LBF20406AM15

LBF20406AM15: Difference between revisions

Latest revision as of 06:42, 8 November 2010

Navigation

Tools